Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	35D0408585	01/27/2022
Name of Provider or Supplier	**Street Address, City, State**	
Langdon Prairie Health	909 2nd St, Langdon, ND	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on American Proficiency Institute proficiency testing record review and staff interview, the laboratory failed to achieve satisfactory performance in proficiency testing for Partial Thromboplastin Time for two of three consecutive testing events in 2021 (Event 2 and Event 3), resulting in unsuccessful performance. (Refer to D2130)
D2130	HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive

	events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on proficiency testing record review and staff interview, the laboratory failed to achieve satisfactory performance in proficiency testing for the analyte Partial Thromboplastin Time (PTT) two of three consecutive events in 2021 (Event 2 and Event 3), resulting in unsuccessful performance. Findings include: 1. Review of 2021 American Proficiency Institute (API) proficiency testing reports on 01/27/22 for the analyte PTT (measured in seconds) revealed the following results: Event 2 - 40% Sample Lab Results Acceptable Range #06 62 34 - 47 #07 50 52 - 71 #08 24 24 - 34 #09 27 26 - 36 #10 52 94 - 128 Event 3 - 40% Sample Lab Results Acceptable Range #11 50 52 - 72 #12 38 36 - 49 #13 24 25 - 35 Sample Lab Results Acceptable Range #14 26 26 - 36 #15 61 33 - 46 The specialty of hematology requires a score of 80% or greater for satisfactory performance. 2. During interview at 10:30 a.m. on 01/26/22, a testing personnel (#1) confirmed the laboratory scored 40% on Events 2 and 3 in 2021 for PTT.